5-(N-oxyaza)-7-substituted-1,4-dihydroquinoxaline-2,3-diones: Novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA, and kainate receptors

Journal of Medicinal Chemistry

Volumn 40, Issue 22, 1997, Pages 3679-3686

  Cai, Sui Xiong ^a   Huang, Jin Cheng ^a   Espitia, Stephen A ^a   Tran, Minhtam ^a   Ilyin, Victor I ^a   Hawkinson, Jon E ^a   Woodward, Richard M ^a   Weber, Eckard ^a   Keana, John F W ^a,b  

^a Department of Pharmacokinetics and Drug Metabolism   (United States)

^b UNIVERSITY OF OREGON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLORO 5 (N OXYAZA) 1,4 DIHYDROQUINOXALINE 2,3 DIONE; 7 NITRO 5 (N OXYAZA) 1,4 DIHYDROQUINOXALINE 2,3 DIONE; AMPA RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; QUINOXALINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN DISEASE; BRAIN ELECTROPHYSIOLOGY; BRAIN PROTECTION; DRUG POTENCY; NONHUMAN; RAT; STROKE;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; EXCITATORY AMINO ACID ANTAGONISTS; KAINIC ACID; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED DBA; QUINOXALINES; RATS;

EID: 0000088717     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970396y     Document Type: Article

References (47)

1. (a) Monaghan, D. T.; Bridges, R. J.; Cotman, C. W. The Excitatory Amino Acid Receptors: Their Classes, Pharmacology, and Distinct properties in the Function of the Central Nervous System. Annu. Rev. Pharmacol. Toxicol. 1989, 29, 365-402.
2. (b) Johnson, R. L.; Koerner, J. F. Excitatory Amino Acid Neurotransmission. J. Med. Chem. 1988, 31, 2057-2066.
3. Gasic, G. P.; Hollmann, M. Molecular Neurobiology of Glutamate Receptors. Annu. Rev. Physiol. 1992, 54, 507-36.
4. Seeberg, P. H. The Molecular Biology of Mammalian Glutamate Receptor Channels. Annu. Rev. Neurosci. 1993, 16, 359-365.
5. Knopfel T.; Kuhn, R.; Allgeier, H. Metabotropic Glutamate Receptors: Novel Targets for Drug Development. J. Med. Chem. 1995, 38, 1417-1426.
6. Meldrum, B.; Garthwaite, J. Excitatory Amino Acid Neurotoxicity and Neurodegenerative Disease. Trends Pharmacol. Sci. 1990, 11, 379-387.
7. Lipton, S. T.; Rosenberg, P. A. Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders. New. Eng. J. Med. 1994, 330, 613-622.
8. Doble, A. Excitatory Amino Acid Receptors and Neurodegeneration. Therapie 1995, 50, 319-337.
9. Muir, K. W.; Lees, K. R. Clinical Experience with Excitatory Amino Acid Antagonist Drugs. Stroke 1995, 26, 503-513.
10. (a) Wong, E. H. F.; Kemp, J. A. Sites for Antagonism on the N-Methyl-D-aspartate Receptor Channel Complex. Annu. Rev. Pharmacol. Toxicol. 1991, 31, 401-425.
11. (b) Bigge, C. F. Structural Requirements for the Development of Potent N-Methyl-D-aspartic Acid Receptor Antagonists. Biochem. Pharmacol. 1993, 45, 1547-1561.
12. (c) Leeson, P. D.; Iversen, L. L. The Glycine Site on the NMDA Receptor: Structure-Activity Relationships and Therapeutic Potential. J. Med. Chem. 1994, 37, 4053-4067.
13. Bigge, C. F.; Boxer, P. A.; Ortwine, D. F. AMPA/Kainate Receptors. Current Pharm. Design 1996, 2, 397-412.
14. (a) Sheardown, M. J.; Nielsen, E. Q.; Hansen, A. J.; Jacobsen, P.; Honore, T. 2.3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline: A Neuroprotectant for Cerebral Ischemia. Science 1990, 247, 571-574.
15. (b) Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Kuruya, T.; Murase, K. 6-(1H-Imidazol-l-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione Hydrochloride (YM90K) and Related Compounds: Structure-Activity Relationships for the AMPA-Type Non-NMDA Receptor. J. Med. Chem. 1994, 37, 467-475.
16. Ohmori, J.; Kubota, H.; Shimizu-Sasarnata, M.; Okada, M.; Sakamoto, S. Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionate Receptor Antagonists: Synthesis and Structure-Activity Relationships of 6-(1H-Imidazol-1-yl)-7-nitro-2,3-(1H,4H)-pyrido[2,3-b]pyrazinedione and Related Compounds. J. Med. Chem. 1996, 39, 1331-1338.
17. (a) Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Leander, J. D.; Schoepp, D. D. (3SR,4aRS,6RS,8aRS)-6-[2-(1H-Tetrazol-5-yl)ethyl]decahydroisoquinoline-3- carboxalic Acid: A structurally Novel, Systemically Active, Competitive AMPA Receptor Antagonist. J. Med. Chem. 1993, 36, 2046-2048.
18. (b) Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-Activity Studies of 6-(Tetrazolylalkyl)-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 1. Effects of Stereochemistry, Chain Length, and Chain Substitution. J. Med. Chem. 1996, 39, 2219-2231.
19. (c) Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Bleisch, T.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-Activity Studies of 6- Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity. J. Med. Chem. 1996, 39, 2232-2244.
20. (a) Tarnawa, I.; Berzsenyi, P.; Andrasi, F.; Botka, P.; Hamoni, T.; Ling, I.; Korosi, J. Structure-Activity Relationships of 2,3-Benzodiazepine Compounds with Glutamate Antagonistic Action. Bio. Med. Chem. Lett. 1993, 3, 99-104.
21. (b) Rogawski, M. A. Therapeutic Potential of Excitatory Amino Acid Antagonists: Channel Blockers and 2,3-Benzodiazepines. Trends Pharmacol. Sci. 1993, 14, 325-331 .
22. (c) Vizi, E. S.; Mike, A.; Tarnawa, I. 2,3-Benzodiazepines (GYKI 52466 and Analogs): Negative Allosteric Modulators of AMPA Receptors. CNS Drug Rev. 1996, 2, 91-126.
23. Anderson, B. A.; Hansen, M. M.; Harkness, A. R.; Henry, C. L.; Vicenzi, J. T.; Zmijewski, M. J. Application of a Practical Biocatalytic Reduction to an Enantioselective Synthesis of the 5H-2,3-Benzodiazepine LY300164. J. Am. Chem. Soc. 1995, 117, 12358-12359.
24. Thomas, R. J. Excitatory Amino Acids in Health and Disease. J. Am. Geriatrics Soc. 1995, 43, 1279-89.
25. Czuczwar, S. J.; Borowicz, K. K.; Kleinrok, Z.; Tutka, P.; Zarnowski, T.; Turski, W. A. Influence of Combined Treatment with NMDA and Non-NMDA Receptor Antagonists on Electroconvulsions in Mice. Eur. J. Pharmocot. 1995, 281, 327-333.
26. Zhou S.; Bonasera, L.; Carlton, S. M. Peripheral Administration of NMDA, AMPA or KA Results in Pain Behaviors in Rats. NeuroReport 1996, 7, 895-900,
27. Buchan, A. M.; Lesiuk, H.; Barnes, K. A.; Li, H.; Huang, Z.-G.; Smith, K. E.; Xue, D. AMPA Antagonists: Do They Hold More Promise for Clinical Stroke Trials Than NMDA Antagonists? Stroke, Suppl I. 1993, 24, I-148-152.
28. Carling, R. W.; Leeson, P. D.; Moore, K. W.; Smith, J. D.; Moyes, C. R.; Mawer, I. M.; Thomas, S.; Chan, T.; Baker, R.; Foster, A. C.; Grimwood, S.; Kemp, J. A.; Marshall, G. R.; Tricklebank, M. D.; Saywell, Kay L. 3-Nitro-3,4-dihydro-2(1H)-quinolones. Excitatory Amino Acid Antagonists Acting at Glycine-Site NMDA and (RS)-α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors. J. Med. Chem. 1993, 36, 3397-3408.
29. Bigge, C. F.; Malone, T. C.; Boxer, P. A.; Nelson, C. B.; Ortwine, D. F.; Schelkun, R. M.; Retz, D. M.; Lescosky, L. J.; Borosky, S. A.; Vartanian, M. G.; Schwarz, R. D.; Campbell, G. W.; Robichaud, L. J.; Watjen, F. Synthesis of 1,4,7,8,9,10-Hexahydro-9-methyl-6-nitropyrido[3,4-f]-quinoxaline-2,3-dione and Related Quinoxalinediones: Characterization of α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (and N-Methyl-D-aspartate) Receptor and Anticonvulsant Activity. J. Med. Chem. 1995, 38, 3720-3740.
30. Ornstein, P. L.; Arnold, M. B.; Allen, N. K.; Leander, J. D.; Tizzano, J. P.; Lodge, D.; Schoepp, D. D. (3SR,4aRS,6SR,8aRS)-6-(1H-Tetrazol-5-yl)decahydroisoquinoline-3-carboxalic Acid, a Novel, Competitive, Systemically Active NMDA and AMPA Receptor Antagonist. J. Med. Chem. 1995, 38, 4885-4890.
31. Cordi, A. A.; Desos, P.; Rancfel, J. C. R.; Lepagnol, J. Structure-Activity Relationships in a Series of 3-Sulfonylamino-2(1H)-quinolones, as New AMPA/Kainate and Glycine Antagonists. Bio. Med. Chem. 1995, 3, 129-141.
32. Keana, J. F. W.; Kher, S. M.; Cai, S. X.; Dinsmore, C. M.; Glenn, A. G.; Guastella, J.; Huang, J. C.; Lu, Y.; Ilyin, V.; Lu, Y.; Mouser, P. L.; Woodward, R. M.; Weber, E. Synthesis and Structure-Activity Relationships of Substituted 1,4-Dihydroquinoxaline-2,3-diones (QXs): Antagonists of the Glycine Site on the NMDA Receptor and of Non-NMDA Glutamate Receptors. J. Med. Chem. 1995, 38, 4367-4379.
33. Woodward, R. M.; Huettner, J. E.; Guastella, J.; Keana, J. F. W.; Weber, E. In Vitro pharmacology of ACEA-1021 and ACEA-1031: Systemically Active quinoxalinediones with High Affinity and Selectivity for N-Methyl-D-aspartate Receptor Glycine Sites. Mol. Pharmacol. 1995, 47, 568-581.
34. Tran, M.; Lutfy, K.; Xu, Z.; Cai, S. X.; Keana, J. F. W.; Weber, E. The Anticonvulsant Structure-Activity Relationship of a Series of Novel NMDA Receptor/Glycine Site Antagonists in the Maximal Electroshock Seizure (MES) Model in Mice. Presented at 25th Annual Meeting of Society for Neuroscience, San Diego, CA. November, 1995. Abstract 84, 18.
35. Israel, M.; Day, A. R. Preparation of Pyrido-(2,3)-pyrazines, Pyrido-(3,4)-pyrazines and imidazo-(b)-pyridines. J. Org. Chem. 1959, 24, 1455-1460.
36. Cai, S. X.; Zhou, Z.-L.; Huang, J.-C; Whittemore, E. R.; Egbuwoku, Z. O.; Lu, Y. Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Synthesis and Structure-Activity Relationships of l,2,3,4-Tetrahydroquinoline-2,3,4-trione 3-Oximes; Novel and Highly Potent Antagonists for the NMDA Receptor Glycine Site. J. Med. Chem. 1996, 39, 3248-3255.
37. Hawkinson, J. E.; Espitia, S. A. Effects of Thiocyanate and AMPA Receptor Ligands on (S)-5-Fluorowillardiine, (S)-AMPA and (R,S)-AMPA Binding. Eur. J. Pharmacol. 1997, 329, 213-221.
38. 3H]Kainate Binding. Eur. J. Pharm. Molec. Pharmacol. Sect. 1993, 246, 195-204.
39. Monyer, H. R.; Sprengel, R.; Schoepfer, A.; Herb, M.; Higuchi, H.; Lomeli, N.; Burnashev, B.; Sakmann B.; Seeburg, P. H. Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes. Science 1992, 256, 1217-1221.
40. Ilyin, V. I.; Whittemore, E. R.; Tran, M.; Shen, K.-Z.; Cai, S. X.; Kher, S. M.; Keana, J. F. W.; Weber, E.; Woodward, R. M. Pharmacology of ACEA-1416: A Potent Systemically Active N-Methy1-D-aspartate Receptor Glycine Site Antagonist. Eur. J. Pharmacol. 1996, 310, 107-114.
41. Woodward, R. M.; Huettner, J. E.; Tran, M.; Guastella, J.; Keana, J. F. W.; Weber, E. Pharmacology of 5-Chloro-7-(trifluoromethyl)-1,4-dihydro-2,3-quinoxalinedione: A Novel Systemically Active Ionotropic Glutamate Receptor Antagonist. J. Pharmacol. Exp. Thera. 1995, 275, 1209-1218.
42. Cai, S. X.; Kher, S. M.; Zhou, Z.-L.; Ilyin, V. I.; Espitia, S. A.; Tran, M.; Hawkinson, J. E.; Woodward, R. M.; Weber, E.; Keana, J. F. W. Structure-Activity Relationships of Alkyl and Alkoxy Substituted 1,4-Dihydroquinoxaline-2,3-diones: Potent and Systemically Active Antagonists for the Glycine Site of the NMDA Receptor. J. Med. Chem. 1997, 40, 730-738.
43. 14C-labeled material and by UV for (N-oxyaza)-QX 12a.
44. Hansch, C.; Bjorkroth, J. P.; Leo, A. J. Hydrophobicity and Central Nervous System Agents: On the Principle of Minimal Hydrophobicity in Drug Design. Pharm. Sci. 1987, 76, 663-687.
45. Lutfy, K.; Cai, S. X.; Woodward, R. M.; Weber, E. Antinociceptive Effects on NMDA and Non-NMDA Receptor Antagonists in the Tail Flick Test in Mice. Pain 1997, 70, 31-40.
46. Daniell, G.; Marek, P.; Weber, E. Unpublished results.
47. Leff, P.; Dougall, I. G. Further Concerns over Cheng-Prusoff Analysis. Trend. Pharmacol. Sci. 1993, 14, 110-112.